Xiulei Mo
Seminars
Wednesday 27th January 2027
Panel Discussion: De-Risking Molecular Glue Development: What Does It Take to Build a Clinically and Commercially Successful Programme?
4:00 pm
- How can developers integrate proteomics, mechanistic biology, translational biomarkers, and emerging clinical data to identify safety liabilities early and improve confidence in candidate selection?
- What are the most important scientific, clinical, regulatory, and commercial risks facing molecular glue programmes today, and how should biotech leaders, investors, and drug developers assess them when making development and funding decisions?
- As more molecular glues advance toward the clinic, what frameworks are needed to evaluate off-target effects, long-term biological consequences, and programme differentiation to enable informed go/no-go, partnering, and investment decisions?
Thursday 28th January 2027
Activating the Undruggable with neoCMG101 to Expand Therapeutic Opportunities Beyond Degradation
11:30 am
- Developing neoCMG101 as a molecular glue activator to drive targeted protein function rather than protein destruction, demonstrating the potential of glue-mediated activation strategies
- Elucidating the structural and mechanistic basis of activation to understand how induced proximity can reprogram cellular signalling, providing a framework for future activator-glue discovery
- Translating activator biology into therapeutic opportunity to address disease drivers beyond the reach of conventional degraders, broadening the molecular glue modality.
